How Do MMN and CIDP Differ? Symptoms, Tests, Treatment

Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are both immune-mediated neuropathies, meaning they occur when the body’s immune system mistakenly attacks the peripheral nerves. While they share similarities, they typically affect the body in distinctly different ways. The key differences lie in the types of symptoms you experience, whether those symptoms are symmetrical, and how the condition responds to certain treatments, particularly steroids ^[1][2].

Because symptoms can overlap, a progressive or unexplained weakness should always be evaluated by a neurologist rather than trying to diagnose it based on symptoms alone ^[3].

Typical Symptom Patterns

One of the most noticeable differences between the two conditions is how and where symptoms typically appear. However, it is important to remember that these are usual patterns, not absolute rules:

• MMN is typically asymmetrical and motor-predominant: MMN usually causes slowly progressive weakness that affects one side of the body more than the other, particularly in the forearms and hands ^[1][4]. It predominantly attacks motor nerve fibers (the nerves responsible for movement), meaning people experience weakness, muscle twitching, and cramping ^[1]. While MMN is primarily a motor condition, a small minority of people may experience minor sensory symptoms or have minor sensory nerve changes ^[1][5].
• CIDP is usually symmetrical and includes sensory symptoms: In contrast, classic CIDP usually produces weakness that affects both sides of the body equally, involving both proximal (closer to the trunk, like hips and shoulders) and distal (farther away, like hands and feet) muscles ^[4][2]. CIDP also frequently involves sensory nerve fibers, leading to symptoms like numbness, tingling, or loss of feeling, and often loss of reflexes ^[6][7].

Important Exceptions: There are variants of CIDP, such as Lewis-Sumner syndrome (also called MADSAM) or pure motor CIDP, which can be asymmetric or mostly involve motor nerves, making them look very similar to MMN ^[8][4]. This is why comprehensive testing is critical.

Diagnosis and Testing

When a doctor performs an electromyography (EMG)—a test that records electrical activity in muscles—and nerve conduction studies, the findings are used to support the diagnosis, alongside your symptom history and physical examination ^[3][1].

• In MMN, doctors look for a focal motor conduction block, meaning the electrical signal is interrupted in specific motor nerves at points where the nerve isn’t typically compressed, while the sensory nerves in that same area function normally ^[9][1]. However, a conduction block may not be detectable in every person with MMN, and it is not unique to MMN ^[10]. Blood tests checking for anti-GM1 antibodies can also support an MMN diagnosis, but these antibodies are only present in about half of MMN patients, so a negative test does not rule it out ^[11][12].
• In CIDP, tests typically show broader evidence of demyelination (damage to the myelin sheath, the protective coating around nerves) across multiple nerves, often involving sensory nerves, though the exact pattern varies by CIDP subtype ^[13][4].

Difference in Treatment Response

Distinguishing between MMN and CIDP is critical because they respond very differently to standard therapies ^[2].

• Intravenous Immunoglobulin (IVIG): IVIG is an effective, established treatment for both conditions ^[2][14]. While it is one of several first-line options for CIDP, it is the best-supported first-line treatment for MMN ^[14][2]. Subcutaneous immunoglobulin (SCIg) may also be used as a maintenance option for some patients with MMN or CIDP after stabilizing on IVIG ^[14][15]. Note that IVIG is a management therapy, not a cure, and response varies.
• Steroids and Plasma Exchange: Corticosteroids (such as prednisone) are a common, effective first-line treatment for CIDP ^[2][14]. However, corticosteroids are not recommended for MMN, as they are ineffective and may even worsen weakness ^[11][16]. Never start, stop, or change steroid medications without your clinician’s guidance. Similarly, plasma exchange (a procedure that removes and replaces plasma, reducing circulating antibodies and other factors) is a treatment option for CIDP but is not typically effective for MMN ^[2][11].

Quick Comparison Summary

Safety Note: Contact your care team promptly if you experience unexpectedly rapid worsening of symptoms, new swallowing or breathing problems, or a major loss of function. These changes do not fit the usual slowly progressive nature of MMN or classic CIDP and require immediate medical assessment.